Peptide-based diagnostics, like gallium-68 DOTATATE, enhance cancer imaging and detection with greater sensitivity and specificity, enabling earlier and more precise disease monitoring.

Aulos Bioscience has dosed the first patient in a Phase 2 trial evaluating AU-007, avelumab, and low-dose aldesleukin for non-small cell lung cancer (NSCLC).

A Phase 1 clinical trial evaluated GPC3-specific CAR T-cells armed with IL-15 in adults and children with GPC3-expressing solid tumors, including hepatocellular carcinoma.

The CHORMES study is a randomized, double-blind, placebo-controlled trial investigating mesoglycan for treating acute hemorrhoidal disease (HD).

India is now a central location for clinical trials focused on advancing HIV treatment, exploring new drug candidates and therapies.

The RESOLUTION trial demonstrated that Vyepti (eptinezumab) is effective for patients with chronic migraine and medication-overuse headache (MOH).

A multicenter study identified digital gait measures using wearable sensors as potential outcome measures for clinical trials in spastic paraplegia type 7 (SPG7).

Sanofi Korea will launch Beyfortus (nirsevimab) early next year to prevent RSV in infants, following its approval by the Ministry of Food and Drug Safety.

U.S. Renal Care has enrolled the first patients in the VOICE trial, assessing Vafseo (vadadustat) for anemia in chronic kidney disease (CKD) patients on dialysis.

Resalis Therapeutics has begun a Phase 1 clinical trial for RES-010, a non-coding RNA-based therapy targeting obesity.

Retifanlimab received accelerated FDA approval in March 2023 for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), demonstrating a 52% objective response rate in clinical trials.

InventisBio's D-2570, an oral TYK2 inhibitor, demonstrated significant efficacy in treating moderate to severe plaque psoriasis in a Phase 2 trial.

A study in _NEJM AI_ validates the Sepsis ImmunoScore™ as an accurate diagnostic tool for sepsis and predictor of adverse outcomes.

Aquablation shows a significant decrease in IPSS scores by approximately 15 points after 5 years, regardless of prostate size, indicating sustained symptom relief.

The European Union prioritizes a "conditional authorization" for COVID-19 vaccines, emphasizing thorough data checks and manufacturer liability.

Next-generation sequencing (NGS) is crucial for personalizing treatment decisions in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, identifying actionable mutations like PIK3CA, AKT, and P10.

Pooled analysis of Phase II/III data reveals that imetelstat provides consistent clinical benefits in patients with myelodysplastic syndromes (MDS).

Neurologist Matthew Schrag highlights the increasing prevalence of research misconduct in Alzheimer's disease studies, which he believes has slowed the development of effective treatments.

A phase III trial showed that adding toripalimab to chemotherapy significantly improved progression-free survival in extensive-stage small cell lung cancer.

Dewpoint Therapeutics and Mitsubishi Tanabe Pharma have entered a collaboration to develop a novel ALS drug, potentially worth up to $480 million.